IP Library Granted Patent US 9,763,890
Granted Patent B2
US 9,763,890 · App. 15/091,825 · Granted Sep 19, 2017

Bacterial ghosts as carrier and targeting vehicles

Inventors: Werner Lubitz (Vienna, AT); Veronika Huter (Leobersdorf, AT)
Assignee: WERNER LUBITZ
A61K9/5068A61K38/465A61K48/00C12N15/87C12Y301/03001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,763,890
App. No.
15/091,825
Granted
Sep 19, 2017
Kind
B2
Abstract

The invention concerns the use of bacterial ghosts as carrier and targeting vehicles for active substances.

Claims (13)

1. A method for preparation of a bacterial ghost containing an active substance encapsulated therein, comprising:

(i) preparing a bacterial ghost comprising a receptor, wherein the receptor is a heterologously expressed polypeptide integrated into a cytoplasmic membrane of the bacterial ghost comprising the receptor, and

(ii) encapsulating the active substance in the bacterial ghost comprising the receptor prepared in step (i), wherein the active substance is present in the bacterial ghost in the immobilized form by interactions with the receptor.

2. The method of claim 1 , wherein the active substance is immobilized on the receptor by non-covalent interactions.

3. The method of claim 1 , wherein the active substance is immobilized on the receptor by non-covalent interactions that are not antibody-antigen binding.

4. The method of claim 1 , wherein the active substance is not an antibody.

5. The method of claim 1 , wherein the active substance is immobilized by non-covalent interactions between avidin or streptavidin and biotin or biotin analogs on the receptor located on an inner side of the cytoplasmic membrane of the bacterial ghost.

6. The method of claim 1 , wherein the heterologously expressed polypeptide is a fusion polypeptide.

7. The method of claim 1 , wherein the heterologously expressed polypeptide is a fusion polypeptide containing streptavidin or avidin.

8. The method of claim 1 , wherein the active substance is a fusion polypeptide.

9. The method of claim 1 , wherein the active substance is derivatized with receptor binding groups.

10. The method of claim 1 , wherein the active substance is a biotinylated active substance.

11. The method of claim 1 , wherein the active substance is biotinylated alkaline phosphatase.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2016
From: HUTER, VERONIKA
To: LUBITZ, WERNER
Reel/Frame 039669/0256 →
Priority Claims (1)
DE 199 09 770 · Mar 5, 1999 · national
Continuity (3)
Continuation 13282144 · Oct 26, 2011
Continuation 09914864
Related Publication 20160220499A1 · Aug 4, 2016